Business
Biocytogen Enters into Agreement with Merck, KGaA, Darmstadt, Germany to Advance Antibody-Conjugated Lipid-Based Delivery Solutions
BEIJING, September 04, 2025--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies and Merck KGaA, Darmstadt, Germany, a leading science and technology company, have entered into an evaluation and option agreement to advance the development of antibody-conjugated lipid-based delivery solutions for nucleic acid payloads, such as antibody-conjugated
About this update from Merck Kgaa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":270,"url":"https://media.zenfs.com/en/business-wire.com/b7f997c7b00577a54ee35bde8e764947"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/RR0WN_NSjmUhIaNdwxyb0Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/b7f997c7b00577a54ee35bde8e764947","width":480,"height":270}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/fd59606bfba5e0530088a9cc34e83f61"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PnCkHv3M4hAIvUvpl0ppQQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/fd59606bfba5e0530088a9cc34e83f61","width":480,"height":480}}},{"type":"text","content":"BEIJING, September 04, 2025--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies and Merck KGaA, Darmstadt, Germany, a leading science and technology company, have entered into an evaluation and option agreement to advance the development of antibody-conjugated lipid-based delivery solutions for nucleic acid payloads, such as antibody-conjugated lipid nanoparticle (LNP).","length":543,"tagName":"p"},{"type":"text","content":"Under the terms of the agreement, Biocytogen will provide proprietary, fully human antibodies derived from its RenMice® platform for evaluation in Merck KGaA, Darmstadt, Germany’s antibody-conjugated LNP services. Merck KGaA, Darmstadt, Germany has been granted an exclusive option to acquire rights to selected antibody assets in return for fees and royalties on sales and sublicenses.","length":386,"tagName":"p"},{"type":"text","content":""We are excited to collaborate again with Merck KGaA, Darmstadt, Germany to explore the potential of antibody-conjugated lipid-based delivery systems," said Dr. Yuelei Shen, President and CEO of Biocytogen. "This collaboration highlights the versatility of our fully human antibody platforms and the broad applicati...